NextTrip (NTRP) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	14-May-15
Document Information [Line Items]
Entity Registrant Name	SIGMA LABS, INC.
Entity Central Index Key	788611
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	SGLB
Entity Common Stock, Shares Outstanding		623,344,835
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash	$2,489,660	$2,962,069
Accounts Receivable, net	164,571	117,726
Inventory	62,444	56,175
Prepaid Assets	21,529	29,986
Total Current Assets	2,738,204	3,165,956
Other Assets
Property and Equipment, net	769,979	803,027
Deferred Stock Offering Costs	95,511	95,511
Intangible Assets, net	96,617	95,847
Total Other Assets	962,107	994,385
TOTAL ASSETS	3,700,311	4,160,341
Current Liabilities
Accounts Payable	97,289	309,698
Accrued Expenses	46,162	44,652
Total Current Liabilities	143,451	354,350
TOTAL LIABILITIES	143,451	354,350
Stockholders' Equity
Preferred Stock, $0.001 par; 10,000,000 shares authorized; None issued and outstanding	0	0
Common Stock, $0.001 par; 750,000,000 shares authorized; 623,344,835 issued and 614,767,005 outstanding at March 31, 2015 and 619,741,061 issued and 612,741,061 outstanding at December 31, 2014 and	623,345	619,741
Additional Paid-In Capital	9,985,684	9,798,288
Less Deferred Compensation 8,577,830 and 7,000,000 common shares, respectively	-812,450	-744,200
Retained Earnings (Deficit)	-6,239,719	-5,867,838
Total Stockholders' Equity	3,556,860	3,805,991
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$3,700,311	$4,160,341

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	750,000,000	750,000,000
Common stock, share issued	623,344,835	619,741,061
Common stock, shares outstanding	614,767,005	612,741,061
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance	8,577,830	7,000,000

Unaudited_Condensed_Consolidat

Unaudited Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
INCOME
Services	$185,686	$114,829
Total Revenue	185,686	114,829
COST OF SERVICE REVENUE	24,867	55,889
GROSS PROFIT	160,819	58,940
EXPENSES
Other General and Administration	267,703	249,543
Payroll Expense	72,660	251,945
Non-cash Stock Compensation	122,750	25,200
Research and Development	70,147	0
Total Expenses	533,260	526,688
OTHER INCOME (EXPENSE)
Interest Income	560	842
Interest Expense	0	0
Total Other Income (Expense)	560	842
INCOME (LOSS) BEFORE INCOME TAXES	-371,881	-466,906
Current Income Tax Expense	0	0
Deferred Income Tax Expense	0	0
Net Income (Loss)	($371,881)	($466,906)
Loss per Common Share - Basic and Diluted (in dollars per share)	$0	$0
Weighted Average Number of Shares Outstanding - Basic and Diluted (in shares)	620,621,984	598,842,450

Unaudited_Condensed_Consolidat1

Unaudited Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES
Net Income (Loss)	($371,881)	($466,906)
Noncash Expenses:
Impairment of Intangible Assets	0	0
Amortization	577	577
Depreciation	40,405	1,537
Stock Compensation	122,750	25,200
Warrant Expense	0	0
Change in assets and liabilities:
(Increase) Decrease in Accounts Receivable	-46,845	177,103
(Increase) in Inventory	-6,269	-2,807
Decrease in Prepaid Assets	8,457	8,319
(Decrease) in Accounts Payable	-212,409	-56,247
Increase In Accrued Expenses	1,510	12,720
NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES	-463,705	-300,504
INVESTING ACTIVITIES
Purchase of Furniture and Equipment	-7,357	0
Purchase of Intangible Assets	-1,347	0
NET CASH (USED) BY INVESTING ACTIVITIES	-8,704	0
FINANCING ACTIVITIES
Proceeds from Sale of Stock Subscriptions	0	3,500,000
Stock Offering Costs	0	-181,663
Deferred Stock Offering Costs	0	0
Contributions	0	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	0	3,318,337
NET CASH INCREASE (DECREASE) FOR PERIOD	-472,409	3,017,833
CASH AT BEGINNING OF PERIOD	2,962,069	992,448
CASH AT END OF PERIOD	2,489,660	4,010,281
Supplemental Disclosure for Cash Flow Information Cash paid during the period for:
Interest	0	0
Income Taxes	$0	$0

Supplemental_Schedule_of_Nonca

Supplemental Schedule of Noncash Investing and Financing Activities (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock Issued During Period, Shares, Issued for Services	3,603,774	375,000
Shares Issued, Price Per Share	$0.05	$0.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	1,650,944	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	1,952,830	175,000
Increase (Decrease) in Deferred Compensation	$103,500
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights		14,259,259
Consultant [Member]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights		2,187,500
Equty Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	375,000
Increase (Decrease) in Deferred Compensation	$35,250

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 – Summary of Significant Accounting Policies
	Nature of Business – On September 13, 2010 Sigma Labs, Inc., formerly named Framewaves, Inc., a Nevada corporation (the “Company”), acquired 100% of the shares of B6 Sigma, Inc. by exchanging 6.67 shares of Framewaves, Inc. restricted common stock for each issued and outstanding share of B6 Sigma, Inc. The acquisition has been accounted for as a “reverse purchase”, and accordingly the operations of Framewaves, Inc. prior to the date of acquisition have been eliminated.
	B6 Sigma, Inc., incorporated February 5, 2010, was founded by a group of scientists, engineers and businessmen to develop and commercialize novel and unique manufacturing and materials technologies. The Company believes that some of these technologies will fundamentally redefine conventional quality assurance and control practices by embedding quality assurance and process control into the manufacturing processes in real time. The Company anticipates that its core technologies will allow its clientele to combine advanced manufacturing quality assurance and control protocols with novel materials to achieve breakthrough product potential in many industries including aerospace, defense, oil and gas, bio-medical and power generation.
	As of December 31, 2011, Sigma Labs, Inc. acquired 100% of the shares of Sumner & Lawrence Limited (“Sumner”), a New Mexico Corporation, and La Mancha Company, a New Mexico Corporation, in exchange for 35,000,000 shares of Sigma Labs, Inc. common stock. The operations of Sumner and La Mancha Company prior to the date of acquisition have been eliminated. La Mancha Company and Sumner have since ceased all operations and were dissolved in 2013 and 2014, respectively.
	Basis of Presentation – The accompanying consolidated financial statements have been prepared by the Company in accordance with Article 8 of U.S. Securities and Exchange Commission Regulation S-X. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and 2014 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. Management suggests these condensed consolidated financial statements be read in conjunction with the December 31, 2014 audited consolidated financial statements and notes thereto included in the Company’s Form 10-K. The results of operations for the periods ended March 31, 2015 and 2014 are not necessarily indicative of the operating results for the full year.
	Reclassification – Certain amounts in prior-period financial statements have been reclassified for comparative purposes to conform to presentation in the current-period financial statements.
	Principles of Consolidation – The consolidated financial statements for March 31, 2015 include the accounts of Sigma Labs, Inc. and B6 Sigma, Inc. All significant intercompany balances and transactions have been eliminated.
	Property and Equipment – Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated life has been determined to be three years unless a unique circumstance exists, which is then fully documented as an exception to the policy.
	Fair Value of Financial Instruments – The Company estimates that the fair value of all financial instruments does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets because of the short-term maturity of these financial instruments.
	Income Taxes – The Company accounts for income taxes in accordance with ASC Topic No. 740, “Accounting for Income Taxes.”
	The Company adopted the provisions of ASC Topic No. 740, “Accounting for Income Taxes,” at the date of inception on February 5, 2010. As a result of the implementation of ASC Topic No. 740, the Company recognized no increase in the liability for unrecognized tax benefits.
	The Company has no tax positions at March 31, 2015 and December 31, 2014 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.
	The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the three months ended March 31, 2015, the Company recognized no interest and penalties. The Company had no accruals for interest and penalties at March 31, 2015 and 2014, or December 31, 2014. All tax years starting with 2010 are open for examination.
	Loss Per Share – The computation of loss per share is based on the weighted average number of shares outstanding during the period in accordance with ASC Topic No. 260, “Earnings Per Share.”
	Accounts Receivable and Allowance for Doubtful Accounts - Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. We determine the allowance for doubtful accounts by identifying potential troubled accounts and by using historical experience and future expectations applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded as income when received. The allowance for doubtful accounts at March 31, 2015 and December 31, 2014 was $4,884 and $4,884 respectively.
	Long-Lived and Intangible Assets – Long-lived assets and certain identifiable definite life intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated liquidation value of such long-lived assets, and provides for impairment if such undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. No impairment was recorded in the three months ended March 31, 2015 or the year ended December 31, 2014.
	Recently Enacted Accounting Standards – The FASB established the Accounting Standards Codification (“Codification” or “ASC”) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”). Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) issued under authority of federal securities laws are also sources of GAAP for SEC registrants.
	Recent Accounting Standards Updates (“ASU”) through ASU No. 2014-16 contain technical corrections to existing guidance or affects guidance to specialized industries. These updates have no current applicability to the Company or their effect on the financial statements would not have been significant.
	Cash Equivalents - The Company considers all highly liquid investments with an original maturity of three months or less at date of purchase to be cash equivalents.
	Concentration of Credit Risk - The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.
	Organization Expenditures – Organizational expenditures are expensed as incurred for SEC filings, but capitalized and amortized for income tax purposes.
	Stock Based Compensation – The Company recognizes compensation costs to employees under ASC Topic No. 718, “Compensation – Stock Compensation.” Under ASC Topic No. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements may include stock options, grants of shares of common stock with and without restrictions, performance based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at its fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option or stock grants. Unvested option or stock grants for compensation are included in the Statement of Stockholders’ Equity as a contra-equity account as “Deferred Compensation.”
	Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 505, “Equity Based Payments to Non-Employees.” In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
	Amortization - Utility patents are amortized over a 17 year period. Patents which are pending are not amortized. The customer contacts intangible asset was being amortized over a 3 year period.
	Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated by management. Significant accounting estimates that may materially change in the near future are impairment of long-lived assets, values of stock compensation awards and stock equivalents granted as offering costs, and allowance for bad debts and inventory obsolescence.
	Revenue Recognition – The Company’s revenue is derived primarily from providing services under contracts. The Company recognizes revenue in accordance with ASC Topic No. 605 based on the following criteria: Persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. In general, the Company recognizes service revenue as significant services under the relevant arrangement have been performed.
	Deferred Stock Offering Costs – Costs related to proposed stock offerings (if any) are deferred and will be offset against the proceeds of the offering in additional paid-in capital. In the event a stock offering is unsuccessful, the costs relating to the offering will be written-off directly to expense.
	Inventory – Inventories consist of raw materials used in the production of customized parts totaling $10,796 and work in process components totaling $51,648 which will be sold to customers. Inventories are valued at the lower of cost or market.
	Research and Development – Research and development costs are expensed as they are incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $70,147 and $0, respectively.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 2 – Stockholders’ Equity
	Common Stock
	The Company has authorized 750,000,000 shares of common stock, $0.001 par value.
	On September 13, 2010 the Company closed a share exchange transaction (the “Reorganization”) with the shareholders of B6 Sigma, Inc., a Delaware corporation (“B6 Sigma”), which resulted in B6 Sigma becoming a wholly-owned subsidiary of the Company. Each share of B6 Sigma, Inc. common stock outstanding as at the closing of the Reorganization was exchanged for 6.67 shares of the Company’s common stock. At the closing, B6 Sigma, Inc. also acquired and cancelled 110,700,000 (post-split) shares of the Company’s common stock from three shareholders for the sum of $195,000. Upon the closing of the Reorganization, the Company ceased to be a “Shell” company (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended). As a condition to the closing of the Reorganization, B6 Sigma, Inc. also closed a private offering of $1,000,000 of its common stock contemporaneously with the closing of the Reorganization, which included the conversion of $300,000 of previously issued convertible notes and related interest by B6 Sigma, Inc. into the private offering of common stock.
	Following issuance of the Reorganization shares to the B6 Sigma shareholders and the stock cancellation, the Company had 313,067,400 (post-split) shares of its common stock issued and outstanding. In connection with the closing of the Reorganization, the shareholders of the Company approved a 150:1 forward stock split, and a change of the name of the corporation to Sigma Labs, Inc. Additionally, following completion of the Reorganization, B6 Sigma became a wholly owned subsidiary of the Company.
	In January 2011, the Company commenced a private offering of up to 75,000,000 shares of common stock, $0.001 par value per share, at a price of $0.02 per share of common stock. On April 15, 2011, the Company closed the private offering, pursuant to which the Company issued 55,875,000 shares of the Company’s common stock. Gross proceeds amounted to $1,117,500.
	The placement agent received a total of $105,735 in commissions. The direct cost associated with the stock offering has been reflected as a reduction to Additional Paid-in-Capital. Net proceeds from the sale of stock were $1,011,765. The Company also issued to the agent five year warrants to purchase up to 7,931,250 shares of the Company’s common stock. Such warrants had an exercise price of $0.025 per share and were valued at $158,625. During July 2013, such warrants were exercised using the cashless exercise option resulting in 5,098,661 shares being issued.
	The fair value of the warrants issued was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: risk free interest rate of 2.14%; Volatility of 470 and an expected life of five years. It is assumed that no dividends will be paid during the periods of calculation, resulting in a respective weighted-average fair value per warrant of $0.02. Management believes the resulting warrant values are reasonable.
	On March 9, 2011, our Board of Directors adopted the 2011 Equity Incentive Plan (the “2011 Plan”). On March 31, 2011, the holders of at least a majority of the issued and outstanding shares of common stock of the Company approved the 2011 Plan. Pursuant to the 2011 Plan, the Company is authorized to grant options, restricted stock and stock appreciation rights to purchase up to 31,000,000 shares of common stock to its employees, officers, directors, consultants and advisors. The 2011 Plan provides for awards of incentive stock options, non-statutory stock options, and rights to acquire stock with and without restrictions. Incentive stock options granted under the 2011 Plan are intended to qualify as “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). Non-statutory stock options granted under the 2011 Plan are not intended to qualify as incentive stock options under the Code.
	On January 31, 2013, the Company issued 250,000 shares of the Company’s common stock to a consultant as noncash compensation for services to be rendered valued at $7,500 or $0.03 per share.
	On February 14, 2013, the Company issued 4,000,000 shares of the Company’s common stock to a consultant as noncash compensation for services to be rendered valued at $120,000 or $0.03 per share. Of these shares, 1,250,000 (valued at $37,500) vested during the six months ended June 30, 2013 and 2,750,000 (valued at $82,500) were cancelled in June 2013.
	On March 15, 2013, the Company’s Board of Directors approved the Company’s 2013 Equity Incentive Plan (the “2013 Plan”). The 2013 Plan was approved by holders of at least a majority of the issued and outstanding shares of common stock of the Company on October 10, 2013. Pursuant to the 2013 Plan, the Company is authorized to grant options, shares of common stock with and without restrictions, and stock appreciation rights to purchase up to 30,000,000 shares of common stock to its employees, officers, directors, consultants and advisors.
	On May 10, 2013, the Company issued 500,000 shares of the Company’s common stock to a consultant as noncash compensation for services rendered valued at $12,400 or $0.0248 per share.
	On May 23, 2013, the Company issued 2,000,000 shares of the Company’s common stock to a consultant as noncash compensation for services to be rendered valued at $45,400 or $0.0227 per share. Of these shares, 1,000,000 (valued at $22,700) vested immediately and 1,000,000 (valued at $22,700) remain unvested and are reflected as deferred compensation as of March 31, 2015.
	On July 18, 2013, the Company completed a private placement of 120,000,000 shares of common stock, resulting in aggregate gross proceeds of $1,200,000. Offering costs were approximately $30,054.
	During July 2013, warrants previously issued during 2011 in connection with a private placement were exercised using the cashless exercise option resulting in 5,098,661 shares being issued.
	On August 12, 2013, the Company issued 500,000 shares of the Company’s common stock to a consultant as noncash compensation for services rendered valued at $31,500 or $0.063 per share.
	On August 26, 2013, the Company issued 1,000,000 shares of the Company’s common stock to a director pursuant to the 2011 Plan valued at $65,000 or $0.065 per share.
	On October 31, 2013, in conjunction with the appointment of a director as a member of the Company’s Board of Directors, the Company issued 500,000 shares of the Company’s common stock to the director pursuant to the 2011 Plan as noncash compensation valued at $78,000 or $0.156 per share. Of these shares, 300,000 (valued at $46,800) vested immediately and 200,000 (valued at $31,200) vested during 2014.
	In January 2014, the Company issued 43,750,000 shares of stock to an investor for a total purchase price of $3,500,000. In connection with the purchase and sale of the shares, the Company agreed to issue to the investor a warrant to purchase up to 14,259,259 shares of the Company’s common stock, at an exercise price of $0.15 per share. The warrant has a term of nine months from the date of issuance (January 10, 2014) and had a fair value of approximately $1,212,037. In May 2014, the term of the warrant was extended by nine months to expire in July 2015 and had a fair market value in excess of the remaining fair market value of the original warrant of approximately $1,283,333. A warrant was also issued as part of the offering to a consultant to purchase up to 2,187,500 shares of common stock at $0.08 per share, valued at approximately $271,250. The warrant has a term of two years from the date of issuance (January 10, 2014). Offering costs paid from the proceeds of the offering were approximately $199,089.
	The fair value of the warrant of $1,212,037 was calculated using a Black-Scholes option pricing model with the following assumptions: expected life of nine months, expected volatility of 202%, a risk-free interest rate of 0.09%, and an expected dividend yield of 0%. The fair value of the warrant of $271,250 was calculated using a Black-Scholes option pricing model with the following assumptions: expected life of two years, expected volatility of 201%, a risk-free interest rate of 0.39%, and an expected dividend yield of 0%.
	The fair value of the new warrant related to the extension of the warrant expiration of $1,283,333 (net) was calculated using a Black-Scholes option pricing model with the following assumptions: expected life of 14 months, expected volatility of 226%, a risk-free interest rate of 0.1%, and an expected dividend yield of 0%.
	In February 2014, the Company issued 375,000 shares of stock to a consultant, subject to restrictions. The shares were valued at $0.126 or $47,250. Of these shares, 200,000 (valued at $25,200) vested during the quarter ended March 31, 2014 and 175,000 (valued at $22,050) vested during the quarter ended September 30, 2014.
	In April 2014, the Company issued 850,000 shares of common stock to two employees and one director for services valued at $0.136 per share or $115,600.
	In June 2014, the Company issued 1,250,000 shares of common stock to a consultant as noncash compensation for services to be rendered valued at $0.128 per share or $160,000.
	In June 2014, the Company issued 6,250,000 shares of stock to an investor for a total purchase price of $500,000. In connection with the purchase and sale of the shares, the Company agreed to issue to the investor a warrant to purchase up to 2,037,037 shares of the Company’s common stock, at an exercise price of $0.15 per share. The warrant has a term of one year from the date of issuance (June 4, 2014) and had a fair value of approximately $132,407. A warrant was also issued as part of the offering to a consultant to purchase up to 312,500 shares of common stock at $0.08 per share, valued at approximately $36,250. The warrant has a term of two years from the date of issuance (June 4, 2014). Offering costs paid from the proceeds of the offering were approximately $25,035.
	The fair value of the warrant of $132,407 was calculated using a Black-Scholes option pricing model with the following assumptions: expected life of one year, expected volatility of 163%, a risk-free interest rate of 0.1%, and an expected dividend yield of 0%. The fair value of the warrant of $36,250 was calculated using a Black-Scholes option pricing model with the following assumptions: expected life of two years, expected volatility of 287%, a risk-free interest rate of 0.41%, and an expected dividend yield of 0%.
	In November 2014, the Company issued 1,500,000 shares of stock to a director, subject to restrictions, pursuant to the 2013 Plan. The shares were valued at $0.094 or $141,000. 375,000 shares vested during the three months ended March 31, 2015 and the remaining 1,125,000 shares are scheduled to vest quarterly during the remainder of 2015.
	In March 2015, the Company issued  1,000,000 shares of stock to a director. The Company also issued 500,000 shares of stock to an officer, and an aggregate of  2,103,774 shares of stock to two consultants, subject to vesting restrictions. The shares were issued pursuant to the 2013 Plan. The shares were valued at $0.053 or $191,000. 1,650,944 of the shares vested during the three months ended March 31, 2015 and the remaining 1,952,830 remain unvested as of March 31, 2015, reflecting an increase to deferred compensation of $103,500.
	The Company has authorized 750,000,000 shares of common stock, $0.001 par value. At March 31, 2015, there were 623,344,835 shares issued and outstanding. At December 31, 2014, there were 619,741,061 shares issued and 612,741,061 outstanding, reflecting 7,000,000 issued but unvested shares pursuant to the 2011 Plan and the 2013 Plan. As of March 31, 2015, an aggregate of 150,000 shares and 17,646,226 shares of common stock were reserved for issuance under the 2011 Plan and the 2013 Plan, respectively, including 1,000,000 shares and 7,577,830 shares subject to vesting restrictions under the 2011 Plan and the 2013 Plan, respectively.
	Deferred Compensation
	During April 2011, the Company issued to five employees an aggregate of 20,000,000 shares of the Company’s common stock, subject to restrictions, pursuant to the 2011 Plan. Such shares were valued at the fair value of $400,000 or $0.02 per share. This compensation has been expensed over the vesting period.
	During the year ended December 31, 2012, 7,000,000 shares of unvested common stock valued at $140,000 (previously included in deferred compensation) were cancelled or forfeited.
	During the year ended December 31, 2012, an additional 3,750,000 shares of common stock valued at $75,000 vested and were recorded to expense and as a reduction to deferred compensation.
	During the year ended December 31, 2013, 500,000 shares of unvested common stock valued at $10,000 (previously included in deferred compensation) were cancelled or forfeited.
	During the year ended December 31, 2013, an additional 1,750,000 shares of common stock valued at $35,000 vested and were recorded to expense and as a reduction to deferred compensation.
	During the year ended December 31, 2013, 4,250,000 shares of common stock were issued to consultants at $0.03 per share, 500,000 shares were issued to a consultant at $0.0248 per share, 2,000,000 shares were issued to a consultant at $0.0227 per share, 500,000 shares were issued to a consultant at $0.063 per share, 1,000,000 shares were issued to a consultant at $0.065 per share and 500,000 shares were issued to a director at $0.156 per share. The unvested portion of the shares at December 31, 2013 (1,200,000 unvested shares) increased deferred compensation by $53,900.
	As of December 31, 2013, the balance of unvested compensation cost expected to be recognized was $88,900 and was recorded as a reduction of stockholders’ equity. The unvested compensation was expected to be recognized over the weighted average period of approximately 1 year (through April 8, 2014).
	During the year ended December 31, 2014, 375,000 shares of common stock were issued to a consultant at $0.126 per share.
	During the year ended December 31, 2014, an additional 1,750,000 shares of common stock valued at $35,000 vested and were recorded to expense and as a reduction to deferred compensation.
	During July 2014, the Company issued to three employees an aggregate of 6,000,000 shares of the Company’s common stock, subject to restrictions, pursuant to the 2013 Plan. Such shares were valued at the fair value of $774,000 or $0.129 per share. This compensation is being expensed over the vesting period. As of March 31, 2015, the balance of unvested compensation cost expected to be recognized is $580,500 (4,500,000 shares valued at $0.129) and is recorded as a reduction of stockholders’ equity. The unvested compensation is expected to be recognized over the weighted average period of approximately 3 years (through July 2017).
	In November 2014, the Company issued 1,500,000 shares of stock to a director, subject to restrictions, pursuant to the 2013 Plan. The shares were valued at $0.094 or $141,000. 375,000 shares vested during the three months ended March 31, 2015 and the remaining 1,125,000 shares are scheduled to vest quarterly during the remainder of 2015.
	In March 2015, the Company issued 1,000,000 shares of stock to a director. The Company also issued 500,000 shares of stock to an officer, and an aggregate of  2,103,774 shares of stock to two consultants, subject to vesting restrictions. The shares were issued pursuant to the 2013 Plan. The shares were valued at $0.053 or $191,000. 1,650,944 of such shares vested during the three months ended March 31, 2015 and the remaining 1,952,830 remain unvested as of March 31, 2015, reflecting an increase to deferred compensation of $103,500.
	As of March 31, 2015, the balance of unvested compensation cost expected to be recognized is $812,450 and is recorded as a reduction of stockholders’ equity. The unvested compensation is expected to be recognized over the weighted average period of approximately 2 years (through July, 2017).
	Preferred Stock
	The Company is authorized to issue 10,000,000 shares of preferred stock, $0.001 par value. There were none issued and outstanding at March 31, 2015 or December 31, 2014.
	Warrants
	At March 31, 2015, the Company had four outstanding warrants for a total of 18,796,296 shares. Of these, 16,296,296 are exercisable at $0.15 per share and 2,500,000 are exercisable at $0.08 per shares.
	During July 2013, warrants which had been issued in January 2011 as part of a private offering were exercised using the cashless exercise option resulting in 5,098,661 shares being issued.
	There were no warrants that expired during the periods ending March 31, 2015 or December 31, 2014.

Registration_Statement_on_Form

Registration Statement on Form S-3	3 Months Ended
	Mar. 31, 2015
Registration Statement [Abstract]
Registration Statement [Text Block]	NOTE 3 – Registration Statement on Form S-3
	As previously reported, during September 2014, the Company filed a Registration Statement on Form S-3 with the SEC, which was declared effective by the SEC on December 19, 2014. The Company may offer and sell, from time to time, up to $100,000,000 of securities, including shares of the Company's common stock and preferred stock, debt securities and warrants, either individually or in units, the terms of which will be described in prospectus supplements filed with the SEC, as applicable. Concurrently with the filing of the Registration Statement, the Company entered into an At The Market Offering Agreement, or sales agreement, with Ascendiant Capital Markets, LLC (“Ascendiant”), pursuant to which the Company may offer and sell from time to time through Ascendiant, acting as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $25,000,000. We have agreed to pay Ascendiant a commission rate of 3% of the gross sales price per share of any of our shares of common stock sold through Ascendiant, as agent, under the sales agreement. The offer and sale of our shares through Ascendiant will be registered pursuant to the Registration Statement. As of March 31, 2015, no securities have been sold under the Registration Statement. As of March 31, 2015, the Company was not eligible to use the Registration Statement because the aggregate market value of the Company’s outstanding common stock held by non-affiliates of the Company was less than the minimum required by General Institution I.B.1 of Form S-3 (i.e., $75 million).

Continuing_Operations

Continuing Operations	3 Months Ended
	Mar. 31, 2015
Continuing Operations Disclosure [Abstract]
Continuing Operations Disclosure [Text Block]	NOTE 4 – Continuing Operations
	The Company has sustained losses and has negative cash flows from operating activities since its inception. The Company has also had decreasing revenues in recent periods. However, the Company has raised significant equity capital and is currently developing new product lines to increase future revenues. The Company believes it has adequate working capital and cash to fund operations through 2016 , and has entered into significant revenue contracts that are expected to generate cash flow in the near term.

Loss_Per_Share

Loss Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	NOTE 5 – Loss Per Share
	The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended March 31, 2015 and 2014:
		3 Months Ended
		3/31/15		3/31/14
	Loss from continuing Operations available to Common stockholders (numerator)	$	-371,881	$	-467,095
	Weighted average number of common shares Outstanding used in loss per share during the Period (denominator)		620,621,984		598,842,450
	Dilutive loss per share was not presented as the Company had no common equivalent shares for all periods presented that would affect the computation of diluted loss per share or its effect is anti-dilutive.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 6 – Subsequent Events
	The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no items to disclose.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – The accompanying consolidated financial statements have been prepared by the Company in accordance with Article 8 of U.S. Securities and Exchange Commission Regulation S-X. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and 2014 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. Management suggests these condensed consolidated financial statements be read in conjunction with the December 31, 2014 audited consolidated financial statements and notes thereto included in the Company’s Form 10-K. The results of operations for the periods ended March 31, 2015 and 2014 are not necessarily indicative of the operating results for the full year.
Reclassification, Policy [Policy Text Block]	Reclassification – Certain amounts in prior-period financial statements have been reclassified for comparative purposes to conform to presentation in the current-period financial statements.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation – The consolidated financial statements for March 31, 2015 include the accounts of Sigma Labs, Inc. and B6 Sigma, Inc. All significant intercompany balances and transactions have been eliminated.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment – Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated life has been determined to be three years unless a unique circumstance exists, which is then fully documented as an exception to the policy.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments – The Company estimates that the fair value of all financial instruments does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets because of the short-term maturity of these financial instruments.
Income Tax, Policy [Policy Text Block]	Income Taxes – The Company accounts for income taxes in accordance with ASC Topic No. 740, “Accounting for Income Taxes.”
	The Company adopted the provisions of ASC Topic No. 740, “Accounting for Income Taxes,” at the date of inception on February 5, 2010. As a result of the implementation of ASC Topic No. 740, the Company recognized no increase in the liability for unrecognized tax benefits.
	The Company has no tax positions at March 31, 2015 and December 31, 2014 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.
	The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the three months ended March 31, 2015, the Company recognized no interest and penalties. The Company had no accruals for interest and penalties at March 31, 2015 and 2014, or December 31, 2014. All tax years starting with 2010 are open for examination.
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share – The computation of loss per share is based on the weighted average number of shares outstanding during the period in accordance with ASC Topic No. 260, “Earnings Per Share.”
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts - Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. We determine the allowance for doubtful accounts by identifying potential troubled accounts and by using historical experience and future expectations applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded as income when received. The allowance for doubtful accounts at March 31, 2015 and December 31, 2014 was $4,884 and $4,884 respectively.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Long-Lived and Intangible Assets – Long-lived assets and certain identifiable definite life intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated liquidation value of such long-lived assets, and provides for impairment if such undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. No impairment was recorded in the three months ended March 31, 2015 or the year ended December 31, 2014.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Enacted Accounting Standards – The FASB established the Accounting Standards Codification (“Codification” or “ASC”) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”). Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) issued under authority of federal securities laws are also sources of GAAP for SEC registrants.
	Recent Accounting Standards Updates (“ASU”) through ASU No. 2014-16 contain technical corrections to existing guidance or affects guidance to specialized industries. These updates have no current applicability to the Company or their effect on the financial statements would not have been significant.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents - The Company considers all highly liquid investments with an original maturity of three months or less at date of purchase to be cash equivalents.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk - The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.
Organization Expenditure [Policy Text Block]	Organization Expenditures – Organizational expenditures are expensed as incurred for SEC filings, but capitalized and amortized for income tax purposes.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation – The Company recognizes compensation costs to employees under ASC Topic No. 718, “Compensation – Stock Compensation.” Under ASC Topic No. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements may include stock options, grants of shares of common stock with and without restrictions, performance based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at its fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option or stock grants. Unvested option or stock grants for compensation are included in the Statement of Stockholders’ Equity as a contra-equity account as “Deferred Compensation.”
	Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 505, “Equity Based Payments to Non-Employees.” In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
Depreciation, Depletion, and Amortization [Policy Text Block]	Amortization - Utility patents are amortized over a 17 year period. Patents which are pending are not amortized. The customer contacts intangible asset was being amortized over a 3 year period.
Use of Estimates, Policy [Policy Text Block]	Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated by management. Significant accounting estimates that may materially change in the near future are impairment of long-lived assets, values of stock compensation awards and stock equivalents granted as offering costs, and allowance for bad debts and inventory obsolescence.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition – The Company’s revenue is derived primarily from providing services under contracts. The Company recognizes revenue in accordance with ASC Topic No. 605 based on the following criteria: Persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. In general, the Company recognizes service revenue as significant services under the relevant arrangement have been performed.
Deferred Stock Offering Costs [Policy Text Block]	Deferred Stock Offering Costs – Costs related to proposed stock offerings (if any) are deferred and will be offset against the proceeds of the offering in additional paid-in capital. In the event a stock offering is unsuccessful, the costs relating to the offering will be written-off directly to expense.
Inventory, Policy [Policy Text Block]	Inventory – Inventories consist of raw materials used in the production of customized parts totaling $10,796 and work in process components totaling $51,648 which will be sold to customers. Inventories are valued at the lower of cost or market.
Research and Development Expense, Policy [Policy Text Block]	Research and Development – Research and development costs are expensed as they are incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $70,147 and $0, respectively.

Loss_Per_Share_Tables

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended March 31, 2015 and 2014:
		3 Months Ended
		3/31/15		3/31/14
	Loss from continuing Operations available to Common stockholders (numerator)	$	-371,881	$	-467,095
	Weighted average number of common shares Outstanding used in loss per share during the Period (denominator)		620,621,984		598,842,450

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details Textual) (USD $)	0 Months Ended	3 Months Ended		12 Months Ended
	Sep. 13, 2010	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2011	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions	100.00%
Number Of Shares Exchanged For Each Share Of Acquired Entity (in shares)	6.67
Allowance for Doubtful Accounts Receivable, Current		$4,884			$4,884
Research and Development Expense		70,147	0
Inventory, Raw Materials, Gross		10,796
Inventory, Work in Process, Gross		$51,648
Sumner and La Mancha [Member]
Summary Of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, Purchase Of Assets (in shares)				35,000,000
Business Acquisition, Percentage of Voting Interests Acquired				100.00%
Patents [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Maximum		17 years
Customer Contacts [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Maximum		3 years

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended		1 Months Ended			12 Months Ended	1 Months Ended				0 Months Ended		1 Months Ended		0 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended		12 Months Ended
	Sep. 13, 2010	31-May-14	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2011	Jun. 30, 2014	Jan. 31, 2014	Oct. 31, 2013	Dec. 31, 2014	Apr. 30, 2011	Aug. 26, 2013	Nov. 30, 2014	Jul. 31, 2014	Aug. 12, 2013	10-May-13	Feb. 28, 2014	23-May-13	Feb. 14, 2013	Jan. 31, 2013	Jun. 30, 2013	Jul. 18, 2013	Jan. 31, 2011	Dec. 31, 2012	Jul. 31, 2013	Mar. 15, 2013	Apr. 30, 2014	Mar. 31, 2011
Class of Stock [Line Items]
Common stock, shares authorized			750,000,000								750,000,000
Common stock, par value (in dollars per share)			$0.00								$0.00
Common stock, share issued			623,344,835								619,741,061
Share Based Compensation Arrangement By Share Based Payment Award Number Of Vested Shares (in shares)			1,650,944	200,000	175,000
Preferred stock, shares authorized			10,000,000								10,000,000
Preferred stock, par value (in dollars per share)			$0.00								$0.00
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized			$812,450			$88,900
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Period For Recognition			2 years			1 year
Placement Agent Commissions Received							105,735
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				14,259,259			7,931,250	312,500																		5,098,661
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$0.03
Proceeds from Issuance of Warrants							158,625
Net Proceeds from Sale of Common Stock							1,011,765
Cancellation Of Common Stock Value	110,700,000
Stock Issued During Period, Shares, Stock Splits	313,067,400
Number Of Shares Exchanged For Each Share Of Acquired Entity (in shares)	6.67
Cancellation Of Common Stock Pursuant To Private Offering	1,000,000
Convertible Notes Value Included In Cancellation Of Common Stock	300,000
Payments of Stock Issuance Costs			0	181,663
Stock Issued During Period, Shares, Issued for Services			3,603,774	375,000
Stock Issued During Period, Shares, New Issues		2,187,500
Shares Issued, Price Per Share			$0.05	$0.13														$0.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares			1,952,830	175,000
Common Stock, Value, Issued			623,345								619,741
Fair Value Adjustment of Warrants		1,283,333	0	0
Common Stock, Shares, Outstanding			614,767,005								612,741,061
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																											30,000,000
Increase (Decrease) in Deferred Compensation			103,500
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																										5,098,661
Class of Warrant or Right, Outstanding			18,796,296
Warrants One [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$0.15
Class Of Warrant Or Rights Exercisable			16,296,296
Warrants Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$0.08
Class Of Warrant Or Rights Exercisable			2,500,000
Warrant Expiry Life Five years [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							2.14%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							470.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price							$0.02
Warrant Expiry Life One Year [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate								0.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate								163.00%
Fair Value Adjustment of Warrants								132,407
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%
Warrant Expiry Life Two Year [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate								0.41%	0.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate								287.00%	201.00%
Fair Value Adjustment of Warrants								36,250
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%
Warrant Expiry Life Nine Months [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate									0.09%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate									202.00%
Fair Value Adjustment of Warrants									1,212,037
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate									0.00%
Warrant Expiry Life Fourteen Months [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate									0.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate									226.00%
Fair Value Adjustment of Warrants									1,283,333
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate									0.00%
Director [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Noncash Consideration (in shares)										500,000
Stock Issued During Period, Value, Issued For Noncash Considerations										78,000
Share Based Compensation Arrangement By Share Based Payment Award Number Of Vested Shares (in shares)										300,000	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value										46,800	31,200
Share Based Compensation Arrangement By Share Based Payment Award Number Of Non Vested Fair Value						53,900
Shares Issued, Price Per Share						$0.16				$0.16
Two Employees and One Director [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share)																												$0.14
Common stock, share issued																												850,000
Common Stock, Value, Issued																												115,600
Equity Incentive Plan 2011 [Member]
Class of Stock [Line Items]
Common stock, shares authorized											612,741,061
Common stock, share issued											619,741,061
Share Based Compensation Arrangement By Share Based Payment Award Number Of Vested Shares (in shares)			1,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																										5,098,661
Shares Issued For Employee Equity Plan												20,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross												400,000
Shares Issued For Employee Equity Plan Par Value (in dollars per share)												$0.02
Common Stock, Capital Shares Reserved for Future Issuance			150,000
Shares Issued, Price Per Share													$0.07
Common Stock, Shares, Outstanding											7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																													31,000,000
Equity Incentive Plan 2011 [Member] | Director [Member]
Class of Stock [Line Items]
Shares Issued For Employee Equity Plan													1,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross													65,000
Equity Incentive Plan 2013 [Member]
Class of Stock [Line Items]
Common stock, shares authorized											750,000,000
Common stock, par value (in dollars per share)											$0.00
Common stock, share issued			623,344,835
Share Based Compensation Arrangement By Share Based Payment Award Number Of Vested Shares (in shares)			7,577,830
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized															580,500
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Period For Recognition															3 years
Shares Issued For Employee Equity Plan														1,500,000	6,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross														141,000	774,000
Shares Issued For Employee Equity Plan Par Value (in dollars per share)															$0.13
Stock Issued During Period, Value, Issued for Services			191,000
Common Stock, Capital Shares Reserved for Future Issuance			17,646,226
Shares Issued, Price Per Share			$0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares															4,500,000
Common Stock, Shares, Outstanding			623,344,835
Equity Incentive Plan 2013 [Member] | Director [Member]
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Number Of Vested Shares (in shares)			375,000
Stock Issued During Period, Shares, Issued for Services			1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number			1,125,000
Equity Incentive Plan 2013 [Member] | Officer [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services			500,000
Issue One [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						500,000
Shares Issued, Price Per Share						$0.03
Issue Two [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						2,000,000
Shares Issued, Price Per Share						$0.02
Issue Three [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						500,000
Shares Issued, Price Per Share						$0.02
Issue Four [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						1,000,000
Shares Issued, Price Per Share						$0.06
Issue Five [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						500,000
Shares Issued, Price Per Share						$0.07
Issue [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services						4,250,000
Investor [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								2,037,037
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$0.15
Stock Issued During Period, Shares, New Issues								6,250,000	43,750,000
Stock Issued During Period, Value, New Issues								500,000	3,500,000
Investor [Member] | Warrant [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues									14,259,259
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									0.15
Consultant One [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Noncash Consideration (in shares)								1,250,000								500,000	500,000		2,000,000	4,000,000	250,000
Stock Issued During Period, Value, Issued For Noncash Considerations								160,000								31,500	12,400		45,400	120,000	7,500
Share Based Compensation Arrangement By Share Based Payment Award Number Of Vested Shares (in shares)				200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				25,200	22,050
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$0.08
Proceeds from Issuance of Warrants								25,035
Cancellation Of Common Stock Value	195,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number						1,200,000													1,000,000			2,750,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period																			1,000,000			1,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value																			22,700			37,500
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non vested Value																			22,700			82,500
Stock Issued During Period, Shares, New Issues											375,000							375,000
Stock Issued During Period, Value, New Issues																		47,250
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$0.13
Warrants and Rights Outstanding								36,250
Shares Issued, Price Per Share								$0.13						$0.09		$0.06	$0.02		$0.02	$0.03	$0.03
Consultant One [Member] | Warrant [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues		271,250
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$0.08
Fair Value Adjustment of Warrants									271,250
Consultant Two [Member] | Equity Incentive Plan 2013 [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services			2,103,774
Private Placement [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share)																								$0.00
Stock Issued During Period, Shares, Issued For Noncash Consideration (in shares)												55,875,000												75,000,000
Stock Issued During Period, Value, Issued For Noncash Considerations												1,117,500
Payments of Stock Issuance Costs		199,089																					30,054
Stock Issued During Period, Shares, New Issues																							120,000,000
Shares Issued, Price Per Share																								$0.02
Proceeds from Issuance of Private Placement																							1,200,000
Common Stock [Member]
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Number Of Vested Shares (in shares)						1,750,000					1,750,000														3,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						35,000					35,000														75,000
Share Based Compensation Arrangement By Share Based Payment Award Value Of Unvested Common Stock						$10,000																			$140,000
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Of Unvested Common Stock						500,000																			7,000,000

Registration_Statement_on_Form1

Registration Statement on Form S-3 (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015
Maximum Securities Available for Offering As Per Registration Statement	$100,000,000
Maximum Amount of Offering Price As Per Registration Statement	25,000,000
Percentage Of Commission On Gross Sales Price Per Share	3.00%
Outstanding Common Stock Held by Non Affiliates Aggregate Market Value	$75,000,000

Loss_Per_Share_Details

Loss Per Share (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Schedule of Earnings Per Share [Line Items]
Loss from continuing Operations available to Common stockholders (numerator)	($371,881)	($466,906)
Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) (in shares)	620,621,984	598,842,450